Associations between Allelic Variants of the Human IgH 3′ Regulatory Region 1 and the Immune Response to BNT162b2 mRNA Vaccine
The escalation of Coronavirus disease 2019 (COVID-19) has required the development of safe and effective vaccines against the severe acute respiratory syndrome coronavirus 2-associated (SARS-CoV-2), which is the causative agent of the disease. Here, we determined the levels of antibodies, antigen-sp...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-10-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/9/10/1207 |
| _version_ | 1827678440313061376 |
|---|---|
| author | Mattia Colucci Elisabetta De Santis Beatrice Totti Mattia Miroballo Francesco Tamiro Giovanni Rossi Ada Piepoli Gabriella De Vincentis Antonio Greco Alessandra Mangia Rossella Cianci Lazzaro Di Mauro Giuseppe Miscio Vincenzo Giambra |
| author_facet | Mattia Colucci Elisabetta De Santis Beatrice Totti Mattia Miroballo Francesco Tamiro Giovanni Rossi Ada Piepoli Gabriella De Vincentis Antonio Greco Alessandra Mangia Rossella Cianci Lazzaro Di Mauro Giuseppe Miscio Vincenzo Giambra |
| author_sort | Mattia Colucci |
| collection | DOAJ |
| description | The escalation of Coronavirus disease 2019 (COVID-19) has required the development of safe and effective vaccines against the severe acute respiratory syndrome coronavirus 2-associated (SARS-CoV-2), which is the causative agent of the disease. Here, we determined the levels of antibodies, antigen-specific B cells, against a recombinant GFP-tagged SARS-CoV-2 spike (S) protein and total T and NK cell subsets in subjects up to 20 days after the injection of the BNT162b2 (Pfizer–BioNTech) vaccine using a combined approach of serological and flow cytometry analyses. In former COVID-19 patients and highly responsive individuals, a significant increase of antibody production was detected, simultaneous with an expansion of antigen-specific B cell response and the total number of NK-T cells. Additionally, through a genetic screening of a specific polymorphic region internal to the 3’ regulatory region 1 (3’RR1) of human immunoglobulin constant-gene (IgH) locus, we identified different single-nucleotide polymorphic (SNP) variants associated with either highly or lowly responsive subjects. Taken together, these results suggest that favorable genetic backgrounds and immune profiles support the progression of an effective response to BNT162b2 vaccination. |
| first_indexed | 2024-03-10T06:09:14Z |
| format | Article |
| id | doaj.art-2fe8929e566442de96b962cc06b0a3bf |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T06:09:14Z |
| publishDate | 2021-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-2fe8929e566442de96b962cc06b0a3bf2023-11-22T20:16:54ZengMDPI AGVaccines2076-393X2021-10-01910120710.3390/vaccines9101207Associations between Allelic Variants of the Human IgH 3′ Regulatory Region 1 and the Immune Response to BNT162b2 mRNA VaccineMattia Colucci0Elisabetta De Santis1Beatrice Totti2Mattia Miroballo3Francesco Tamiro4Giovanni Rossi5Ada Piepoli6Gabriella De Vincentis7Antonio Greco8Alessandra Mangia9Rossella Cianci10Lazzaro Di Mauro11Giuseppe Miscio12Vincenzo Giambra13Institute for Stem Cell Biology, Regenerative Medicine and Innovative Therapies (ISBReMIT), Fondazione IRCCS “Casa Sollievo della Sofferenza”, 71013 San Giovanni Rotondo, ItalyInstitute for Stem Cell Biology, Regenerative Medicine and Innovative Therapies (ISBReMIT), Fondazione IRCCS “Casa Sollievo della Sofferenza”, 71013 San Giovanni Rotondo, ItalyInstitute for Stem Cell Biology, Regenerative Medicine and Innovative Therapies (ISBReMIT), Fondazione IRCCS “Casa Sollievo della Sofferenza”, 71013 San Giovanni Rotondo, ItalyInstitute for Stem Cell Biology, Regenerative Medicine and Innovative Therapies (ISBReMIT), Fondazione IRCCS “Casa Sollievo della Sofferenza”, 71013 San Giovanni Rotondo, ItalyInstitute for Stem Cell Biology, Regenerative Medicine and Innovative Therapies (ISBReMIT), Fondazione IRCCS “Casa Sollievo della Sofferenza”, 71013 San Giovanni Rotondo, ItalyDepartment of Hematology and Stem Cell Transplant Unit, Fondazione IRCCS “Casa Sollievo della Sofferenza”, 71013 San Giovanni Rotondo, ItalyHospital Health Department, Fondazione IRCCS “Casa Sollievo della Sofferenza”, 71013 San Giovanni Rotondo, ItalyHospital Health Department, Fondazione IRCCS “Casa Sollievo della Sofferenza”, 71013 San Giovanni Rotondo, ItalyComplex Structure of Geriatrics, Department of Medical Sciences, Fondazione IRCCS “Casa Sollievo della Sofferenza”, 71013 San Giovanni Rotondo, ItalyLiver Unit, Department of Medical Sciences, Fondazione IRCCS “Casa Sollievo della Sofferenza”, 71013 San Giovanni Rotondo, ItalyDipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario “Agostino Gemelli”, IRCCS, 00168 Rome, ItalyClinical Laboratory Analysis and Transfusional Medicine, Fondazione IRCCS “Casa Sollievo della Sofferenza”, 71013 San Giovanni Rotondo, ItalyClinical Laboratory Analysis and Transfusional Medicine, Fondazione IRCCS “Casa Sollievo della Sofferenza”, 71013 San Giovanni Rotondo, ItalyInstitute for Stem Cell Biology, Regenerative Medicine and Innovative Therapies (ISBReMIT), Fondazione IRCCS “Casa Sollievo della Sofferenza”, 71013 San Giovanni Rotondo, ItalyThe escalation of Coronavirus disease 2019 (COVID-19) has required the development of safe and effective vaccines against the severe acute respiratory syndrome coronavirus 2-associated (SARS-CoV-2), which is the causative agent of the disease. Here, we determined the levels of antibodies, antigen-specific B cells, against a recombinant GFP-tagged SARS-CoV-2 spike (S) protein and total T and NK cell subsets in subjects up to 20 days after the injection of the BNT162b2 (Pfizer–BioNTech) vaccine using a combined approach of serological and flow cytometry analyses. In former COVID-19 patients and highly responsive individuals, a significant increase of antibody production was detected, simultaneous with an expansion of antigen-specific B cell response and the total number of NK-T cells. Additionally, through a genetic screening of a specific polymorphic region internal to the 3’ regulatory region 1 (3’RR1) of human immunoglobulin constant-gene (IgH) locus, we identified different single-nucleotide polymorphic (SNP) variants associated with either highly or lowly responsive subjects. Taken together, these results suggest that favorable genetic backgrounds and immune profiles support the progression of an effective response to BNT162b2 vaccination.https://www.mdpi.com/2076-393X/9/10/1207COVID-19vaccineHS1.2IgH locusantigen-specific B cells |
| spellingShingle | Mattia Colucci Elisabetta De Santis Beatrice Totti Mattia Miroballo Francesco Tamiro Giovanni Rossi Ada Piepoli Gabriella De Vincentis Antonio Greco Alessandra Mangia Rossella Cianci Lazzaro Di Mauro Giuseppe Miscio Vincenzo Giambra Associations between Allelic Variants of the Human IgH 3′ Regulatory Region 1 and the Immune Response to BNT162b2 mRNA Vaccine Vaccines COVID-19 vaccine HS1.2 IgH locus antigen-specific B cells |
| title | Associations between Allelic Variants of the Human IgH 3′ Regulatory Region 1 and the Immune Response to BNT162b2 mRNA Vaccine |
| title_full | Associations between Allelic Variants of the Human IgH 3′ Regulatory Region 1 and the Immune Response to BNT162b2 mRNA Vaccine |
| title_fullStr | Associations between Allelic Variants of the Human IgH 3′ Regulatory Region 1 and the Immune Response to BNT162b2 mRNA Vaccine |
| title_full_unstemmed | Associations between Allelic Variants of the Human IgH 3′ Regulatory Region 1 and the Immune Response to BNT162b2 mRNA Vaccine |
| title_short | Associations between Allelic Variants of the Human IgH 3′ Regulatory Region 1 and the Immune Response to BNT162b2 mRNA Vaccine |
| title_sort | associations between allelic variants of the human igh 3 regulatory region 1 and the immune response to bnt162b2 mrna vaccine |
| topic | COVID-19 vaccine HS1.2 IgH locus antigen-specific B cells |
| url | https://www.mdpi.com/2076-393X/9/10/1207 |
| work_keys_str_mv | AT mattiacolucci associationsbetweenallelicvariantsofthehumanigh3regulatoryregion1andtheimmuneresponsetobnt162b2mrnavaccine AT elisabettadesantis associationsbetweenallelicvariantsofthehumanigh3regulatoryregion1andtheimmuneresponsetobnt162b2mrnavaccine AT beatricetotti associationsbetweenallelicvariantsofthehumanigh3regulatoryregion1andtheimmuneresponsetobnt162b2mrnavaccine AT mattiamiroballo associationsbetweenallelicvariantsofthehumanigh3regulatoryregion1andtheimmuneresponsetobnt162b2mrnavaccine AT francescotamiro associationsbetweenallelicvariantsofthehumanigh3regulatoryregion1andtheimmuneresponsetobnt162b2mrnavaccine AT giovannirossi associationsbetweenallelicvariantsofthehumanigh3regulatoryregion1andtheimmuneresponsetobnt162b2mrnavaccine AT adapiepoli associationsbetweenallelicvariantsofthehumanigh3regulatoryregion1andtheimmuneresponsetobnt162b2mrnavaccine AT gabrielladevincentis associationsbetweenallelicvariantsofthehumanigh3regulatoryregion1andtheimmuneresponsetobnt162b2mrnavaccine AT antoniogreco associationsbetweenallelicvariantsofthehumanigh3regulatoryregion1andtheimmuneresponsetobnt162b2mrnavaccine AT alessandramangia associationsbetweenallelicvariantsofthehumanigh3regulatoryregion1andtheimmuneresponsetobnt162b2mrnavaccine AT rossellacianci associationsbetweenallelicvariantsofthehumanigh3regulatoryregion1andtheimmuneresponsetobnt162b2mrnavaccine AT lazzarodimauro associationsbetweenallelicvariantsofthehumanigh3regulatoryregion1andtheimmuneresponsetobnt162b2mrnavaccine AT giuseppemiscio associationsbetweenallelicvariantsofthehumanigh3regulatoryregion1andtheimmuneresponsetobnt162b2mrnavaccine AT vincenzogiambra associationsbetweenallelicvariantsofthehumanigh3regulatoryregion1andtheimmuneresponsetobnt162b2mrnavaccine |